Date: 2014-11-20
Type of information: Collaboration agreement
Compound: Archi-Pex (peptide architectures and formulations) joint research and innovation lab
Company: Ipsen (France) CNRS (France)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On November 20, 2014, Ipsen and French National Center for Scientific Research (CNRS) announced the creation of the Archi-Pex (peptide architectures and formulations) joint research and innovation lab in collaboration with the French Alternative Energies and Atomic Energy Commission (CEA) and the University of Rennes. This is the result of a public-private partnership active since 1999. The joint Archi-Pex lab, supported by the French National Research Agency, seeks to conduct multi-disciplinary research bringing together academic teams in physics and biology with the researchers at Ipsen\'s center for pharmaceutical development based in Dreux (France). The aim is to innovate in the formulation of hormonal peptides and to reduce the development time. Understanding of the pharmaceutical efficacy arising from basic knowledge is the key to Archi-Pex project.
Archi-Pex will focus on developing new sustained-release formulations based on peptide selfassemblies and on accelerating the development of alternative drug delivery systems, particularly in endocrinology.
Financial terms:
Latest news:
